H.C. Wainwright lowered the firm’s price target on 89bio to $31 from $32 and keeps a Buy rating on the shares post the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ETNB:
- 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference